Penn Pharma
Pharmaceutical manufacturer Penn Pharma has reached a significant safety milestone this month, operating for three years without experiencing a reportable accident at its facility in Gwent, South Wales, UK. The new contained manufacturing facility, which opened in September last year, along with the original facility have both been operating safely for a length of time that equates to 1.75 million hours worked by c.300 staff.
Penn Pharma Chief Operating Officer Mark Dean-Netscher said: “With a background £18 million expansion programme and significant construction activity on site, this is a fantastic achievement on our continued journey for operational excellence at Penn.
“We have superb engagement from all of our staff with a very active near miss system and safety-focussed culture in place. Our safety record ranks with the best in the pharmaceutical sector. It shows that Penn applies the same importance to the safety of our staff as we do to the safety of the medicines we supply to patients worldwide.”
Adding to this achievement is Penn Pharma’s retention of its accreditation to the ISO14001 standard for environmental management. This followed an intensive two-day audit by its certification body and was achieved within three days of reaching the three-year safety milestone.
Dean-Netscher concluded: “Penn Pharma is proud of its EHS performance and is committed to achieving further success in the future.”
Penn Pharma delivers integrated drug development, clinical trial supply and manufacturing services to the international healthcare industry.
Penn Pharma Ltd, +44 1495 711 222, www.pennpharm.co.uk.
